Awakening guardian angels: drugging the p53 pathway (Q35014385)

5 August 2017

1 reference

title

Awakening guardian angels: drugging the p53 pathway (English)

1 reference

5 August 2017

4

Alan R Fersht

1 reference

5 August 2017

Christopher J Brown

1

1 reference

5 August 2017

Sonia Lain

series ordinal

2

1 reference

5 August 2017

Chandra S Verma

series ordinal

3

1 reference

5 August 2017

David P Lane

series ordinal

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

5 August 2017

published in

Nature Reviews Cancer

1 reference

5 August 2017

volume

9

1 reference

5 August 2017

issue

12

1 reference

5 August 2017

page(s)

862-873

1 reference

Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein

5 August 2017

cites work

1 reference

Tumor suppressor p53: analysis of wild-type and mutant p53 complexes

21 January 2018

1 reference

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

21 January 2018

1 reference

High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx

21 January 2018

1 reference

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

21 January 2018

1 reference

Characterization, chemical optimization and anti-tumour activity of a tubulin poison identified by a p53-based phenotypic screen

21 January 2018

1 reference

Activation of a unique p53-dependent DNA damage response

21 January 2018

1 reference

Basic cell cycle and cancer research: is harmony impossible?

21 January 2018

1 reference

The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.

21 January 2018

1 reference

Phase I trial of elactocin

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

31 March 2020

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

31 March 2020

1 reference

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

31 March 2020

1 reference

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

31 March 2020

1 reference

A hot spot of binding energy in a hormone-receptor interface

31 March 2020

1 reference

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

31 March 2020

1 reference

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

31 March 2020

1 reference

Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1.

31 March 2020

1 reference

31 March 2020

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

31 March 2020

1 reference

No PUMA, no death: implications for p53-dependent apoptosis

31 March 2020

1 reference

Transcription-independent pro-apoptotic functions of p53.

31 March 2020

1 reference

Modulation of microRNA processing by p53

31 March 2020

1 reference

p53 Protein exhibits 3'-to-5' exonuclease activity

31 March 2020

1 reference

p53: traffic cop at the crossroads of DNA repair and recombination

31 March 2020

1 reference

p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria

31 March 2020

1 reference

p53 modulates RPA-dependent and RPA-independent WRN helicase activity

31 March 2020

1 reference

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling

31 March 2020

1 reference

The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways

31 March 2020

1 reference

Modeling the therapeutic efficacy of p53 restoration in tumors

31 March 2020

1 reference

Restoration of p53 function leads to tumour regression in vivo

31 March 2020

1 reference

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

31 March 2020

1 reference

A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect

31 March 2020

1 reference

p53 in health and disease

31 March 2020

1 reference

The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53?

31 March 2020

1 reference

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

31 March 2020

1 reference

Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity

31 March 2020

1 reference

Inactivation of the p53 pathway in retinoblastoma.

31 March 2020

1 reference

31 March 2020

1 reference

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

31 March 2020

1 reference

Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation

31 March 2020

1 reference

The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype

31 March 2020

1 reference

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

31 March 2020

1 reference

Mutant p53: an oncogenic transcription factor

31 March 2020

1 reference

Transcriptional activities of mutant p53: when mutations are more than a loss

31 March 2020

1 reference

The first 30 years of p53: growing ever more complex

31 March 2020

1 reference

Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain

31 March 2020

1 reference

Pharmacological rescue of mutant p53 conformation and function

31 March 2020

1 reference

Structural basis for understanding oncogenic p53 mutations and designing rescue drugs

31 March 2020

1 reference

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

31 March 2020

1 reference

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

31 March 2020

1 reference

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

31 March 2020

1 reference

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

31 March 2020

1 reference

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

31 March 2020

1 reference

Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.

31 March 2020

1 reference

Structural biology of the tumor suppressor p53.

31 March 2020

1 reference

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

31 March 2020

1 reference

Regulation of the specific DNA binding function of p53

31 March 2020

1 reference

Small peptides activate the latent sequence-specific DNA binding function of p53.

31 March 2020

1 reference

Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells

31 March 2020

1 reference

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

31 March 2020

1 reference

31 March 2020

Curing cancer with p53.

1 reference

Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

31 March 2020

1 reference

Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library

31 March 2020

1 reference

Flexibility: the key to p53 function?

31 March 2020

1 reference

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

31 March 2020

1 reference

Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis

31 March 2020

1 reference

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

31 March 2020

1 reference

Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region

31 March 2020

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

Amplification of a gene encoding a p53-associated protein in human sarcomas

31 March 2020

1 reference

The MDM2 gene amplification database

31 March 2020

1 reference

Tumor suppression and normal aging in mice with constitutively high p53 activity

31 March 2020

1 reference

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

31 March 2020

1 reference

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

31 March 2020

1 reference

Structure-based design of potent non-peptide MDM2 inhibitors

31 March 2020

1 reference

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

31 March 2020

1 reference

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

31 March 2020

1 reference

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

31 March 2020

1 reference

Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design

31 March 2020

1 reference

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

31 March 2020

1 reference

Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53

31 March 2020

1 reference

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

31 March 2020

1 reference

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

31 March 2020

1 reference

Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms

31 March 2020

1 reference

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

31 March 2020

1 reference

MDM2 interacts with MDMX through their RING finger domains

31 March 2020

1 reference

Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein

31 March 2020

1 reference

HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.

31 March 2020

1 reference

Mutual dependence of MDM2 and MDMX in their functional inactivation of p53

31 March 2020

1 reference

MDM2 promotes ubiquitination and degradation of MDMX

31 March 2020

1 reference

DNA damage-induced MDMX degradation is mediated by MDM2.

31 March 2020

1 reference

Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2.

31 March 2020

1 reference

Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

31 March 2020

1 reference

Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis.

31 March 2020

1 reference

Comparative study of the p53-mdm2 and p53-MDMX interfaces

31 March 2020

1 reference

Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX

31 March 2020

1 reference

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide

31 March 2020

1 reference

Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level

31 March 2020

1 reference

Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

31 March 2020

1 reference

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

31 March 2020

1 reference

Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53

31 March 2020

1 reference

Cancer. p53, guardian of the genome

31 March 2020

1 reference

High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter

31 March 2020

1 reference

Pilot screening programme for small molecule activators of p53.

31 March 2020

1 reference

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors

31 March 2020

1 reference

Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis

31 March 2020

1 reference

Mycophenolic acid activation of p53 requires ribosomal proteins L5 and L11

31 March 2020

1 reference

A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.

31 March 2020

1 reference

RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells.

31 March 2020

1 reference

Inhibition of RNA polymerase II as a trigger for the p53 response

31 March 2020

1 reference

Regulation of HDM2 activity by the ribosomal protein L11

31 March 2020

1 reference

Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation

31 March 2020

1 reference

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

31 March 2020

1 reference

Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group

31 March 2020

1 reference

NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro

31 March 2020

1 reference

Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

31 March 2020

1 reference

Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism

31 March 2020

1 reference

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

31 March 2020

1 reference

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53

31 March 2020

1 reference

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis

31 March 2020

1 reference

Negative control of p53 by Sir2alpha promotes cell survival under stress

31 March 2020

1 reference

hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase

31 March 2020

1 reference

Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence

31 March 2020

1 reference

Identification of nuclear export inhibitors with potent anticancer activity in vivo

31 March 2020

1 reference

Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors

31 March 2020

1 reference

Modelling Myc inhibition as a cancer therapy

31 March 2020

1 reference

Structure-based design of molecular cancer therapeutics

31 March 2020

1 reference

Discovering novel ligands for macromolecules using X-ray crystallographic screening

31 March 2020

1 reference

Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases

31 March 2020

1 reference

MDM2 inhibitors for cancer therapy

31 March 2020

1 reference

Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase

31 March 2020

1 reference

Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53

31 March 2020

1 reference

p53 and human cancer: the first ten thousand mutations.

31 March 2020

1 reference

12 December 2020

Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

1 reference

12 December 2020

Family feud in chemosensitvity: p73 and mutant p53.

1 reference

12 December 2020

Control of p53 ubiquitination and nuclear export by MDM2 and ARF.

1 reference

12 December 2020

p53 accumulates but is functionally impaired when DNA synthesis is blocked

1 reference

12 December 2020

Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect

1 reference

12 December 2020

p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2.

1 reference

12 December 2020

Tumor-suppressing gene therapy

1 reference

12 December 2020

The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest.

1 reference

12 December 2020

Cancer-specific viruses and the development of ONYX-015

1 reference

12 December 2020

A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40.

1 reference

12 December 2020

Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53.

1 reference

12 December 2020

Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC2763

1 reference

5 August 2017

1 reference